ResearcherDalian Medical UniversityActive in the last 2 years
Changyuan Wang
Matched on ORCID iD 0000-0002-5669-1483; OpenAlex author ID A5100622771. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: none · 2026: 1 paper
Papers 4
- LINC00852 Enhances Glycolysis and Tumor Immunity in Pancreatic Cancer via the miR‑494‑3p/GPX8 Axis. Co-author DOI 10.1002/jbt.70871↗
- A commentary on 'Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer'. Co-author DOI 10.1097/js9.0000000000001568↗
- Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FAK inhibitors for the potential treatment… Co-author DOI 10.1016/j.ejmech.2022.114607↗
- Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cance… Co-author DOI 10.1016/j.bmc.2017.09.041↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Bole Tian · 2 shared papers, 2024–2026 · strength 0.86
- Yi Li · 1 shared paper, 2024 · strength 0.36
- Xiaodong Ma · 2 shared papers, 2017–2022 · strength 0.22
- Paper Design, synthesis and activity evaluation of isopropylsulfonyl-substituted 2,4- diarylaminopyrimidine derivatives as FA… DOI 10.1016/j.ejmech.2022.114607↗
- Paper Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with en… DOI 10.1016/j.bmc.2017.09.041↗
- Xu Zheng · 1 shared paper, 2022 · strength 0.15
- Xing Li · 1 shared paper, 2022 · strength 0.15
- Yanxia Li · 1 shared paper, 2022 · strength 0.15
- Yanxia Li · 1 shared paper, 2017 · strength 0.06
- He Liu · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.